MONALEESA-7研究:瑞波西利联合内分泌治疗激素受体阳性绝经前晚期乳腺癌的疗效分析  

MONALEESA⁃7 Study:Analysis of the Efficacy of Ribociclib Combined With Endocrine Therapy for Hormone Receptor Positive Premenopausal Advanced Breast Cancer

作　　者：杨梅[1] 黄帅[1] 舒茂 YANG Mei;HUANG Shuai;SHU Mao(Department of Breast Cancer,Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,China)

机构地区：[1]南方医科大学附属广东省人民医院(广东省医学科学院)乳腺肿瘤科,广州510080

出　　处：《循证医学》2023年第2期78-82,共5页The Journal of Evidence-Based Medicine

摘　　要：1文献来源Im SA,Lu YS,Bardia A,et al.Overall survival with ribociclib plus endocrine therapy in breast cancer[J].N Engl J Med,2019,381(4):307-316.2证据水平1b。3背景年轻乳腺癌(<50岁)患者在所有乳腺癌患者中占比很高,且这部分患者中大约三分之二是激素受体(hormone receptor,HR)阳性(定义为雌激素或孕激素受体表达,或两者都表达).

关 键 词：晚期激素受体阳性乳腺癌 CDK4/6抑制剂 靶向治疗 

分 类 号：R737.9[医药卫生—肿瘤]